Fathom Therapeutics, formerly known as Atommap, has raised $47 million in an oversubscribed Series A financing round to advance its artificial intelligence and physics-enabled drug discovery platform. The round was led by Sutter Hill Ventures, with participation from Chemistry, Alexandria Venture Investments, and NY Ventures. The company said the funding will support the continued development of its technology platform, expansion of its scientific team, and efforts to translate AI-powered molecular design into next-generation medicines.

Fathom Therapeutics is a biotechnology company focused on using artificial intelligence, computational methods, and quantum chemistry to design new small-molecule medicines. Formerly operating as Atommap, the company was founded by scientists and researchers with expertise in computational chemistry, artificial intelligence, and drug discovery. Its platform is designed to predict how drug molecules behave inside living cells, helping researchers identify and develop potential therapeutic candidates more efficiently.

The company’s technology combines physics-based modeling with AI to address challenges in traditional drug discovery. Developing new medicines typically requires significant time and resources, with many potential drug candidates failing during the discovery and development process. Fathom Therapeutics aims to improve this process by using computational approaches to better predict molecular behavior before candidates move further into laboratory testing.

Fathom’s platform is focused on designing novel small molecules by analyzing interactions between compounds and biological systems. The company believes that combining artificial intelligence with scientific principles can help researchers explore a broader range of therapeutic possibilities and accelerate the identification of promising drug candidates.

The Series A financing marks a significant milestone for Fathom Therapeutics as it moves to expand its capabilities and advance its research programs. The company plans to use the capital to strengthen its artificial intelligence and computational infrastructure, grow its scientific and operational teams, and continue developing its drug discovery platform.

Sutter Hill Ventures, which led the financing, is a venture capital firm that invests in technology companies across areas including enterprise software, artificial intelligence, and healthcare innovation. The firm has backed numerous technology companies from early stages through periods of significant growth. Its investment in Fathom reflects increasing venture interest in AI-enabled biotechnology platforms that aim to transform pharmaceutical research and development.

Additional investors participating in the round include Chemistry, Alexandria Venture Investments, and NY Ventures. Alexandria Venture Investments is the venture arm of Alexandria Real Estate Equities and focuses on life sciences and technology companies, while NY Ventures supports innovative companies connected to New York’s technology and life sciences ecosystem.

The investment comes as artificial intelligence continues to reshape pharmaceutical research. AI-driven drug discovery companies have attracted growing attention from investors and pharmaceutical organizations seeking ways to reduce development timelines, improve prediction accuracy, and discover medicines that may have been difficult to identify using traditional methods.

Fathom Therapeutics is part of a broader movement toward computationally driven biotechnology, where advanced algorithms and scientific modeling are increasingly used alongside laboratory research. The company’s approach focuses on integrating AI with fundamental scientific principles rather than relying solely on data-driven methods. By combining computational prediction with biological understanding, Fathom aims to improve the efficiency and accuracy of early-stage drug discovery.

The company’s founders, including CEO Huafeng Xu, PhD, Chief Technology Officer Yujie Wu, PhD, and Chief Computational Scientist Jesus Izaguirre, PhD, bring backgrounds in computational science and molecular modeling. Under their leadership, Fathom has developed its platform around the goal of creating more predictive approaches to medicine development.

Beyond advancing internal research programs, the new funding is expected to help Fathom expand partnerships and collaborations within the pharmaceutical and biotechnology sectors. The company aims to provide a technology foundation that can support the discovery of new medicines across multiple therapeutic areas.

As the pharmaceutical industry increasingly adopts artificial intelligence tools, companies like Fathom Therapeutics are working to address one of the most challenging parts of healthcare innovation: creating new medicines faster and more effectively. With its $47 million Series A financing, Fathom is positioned to continue developing its AI-enabled drug discovery platform and advancing its vision of using computational science to improve the future of medicine.

Related Articles